



1. EGA Code of Conduct

A. Are you aware of the existence of the EGA Code of Conduct?

yes no

B. Are you aware that the transfer of value (financial) between the pharmaceutical industry and the healthcare community will have to be published in Europe according to requirements?

yes no

2. Transfer-of-Value

C. In the context of your profession, did you hear or do you have experience in disclosing Transfer-of-Value? If so, individual or aggregate?

D. Do you have any preference on an aggregate or individual (detailed) system for disclosure? Could you explain?

E. Do you have feedback with existing disclosure systems?

3. Your Perception of Disclosure Systems in General

F. What are the benefits versus issues you are associating / experiencing with disclosure? Benefits

G. What would be the impact on your profession/ membership?

4. Disclosing in the Future

H. Do you think disclosure will help to mitigate potential conflict of interest between life science companies and HCPs?

I. Which form of disclosure (aggregate/ individual) better serves the purpose of making potential Conflict of Interest of life science companies and medical associations more transparent?

J. In particular for the disclosing of aggregate R&D values by a company (clinical and non-clinical studies), do you consider the publication of R&D figures helpful for addressing potential Conflicts of interest between the industry and an HCP?

yes

no

If so, what should the aggregate R&D figure entail?

K. What would be your preferred platform for disclosure?

Company Level

Centralized system (ex. National association)

Both

L. Would you use the information? If so, how?

M. Would you have any additional remarks/ recommendation for the EGA disclosing schemes?